Clinical Trial Detail

NCT ID NCT04254107
Title A Safety Study of SGN-TGT in Patients With Advanced Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Seattle Genetics, Inc.
Indications

diffuse large B-cell lymphoma

Hodgkin's lymphoma

lymphoma

stomach carcinoma

lung non-small cell carcinoma

peripheral T-cell lymphoma

Therapies

SGN-TGT

Pembrolizumab + SGN-TGT

Age Groups: senior adult

No variant requirements are available.